Detailed results from the CAPItello-291 phase III trial showed AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus Faslodex in patients with hormone receptor-positive, human epidermal growth factor receptor 2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor).
Retrospective analyses of data from the Suppression of Ovarian Function Trial trial, led by Hologic Inc. and its subsidiary, Biotheranostics Inc., showed that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive breast cancer benefited from the addition of ovarian function suppression to primary adjuvant endocrine therapy.
A study published today by researchers at Fox Chase Cancer Center suggests that independent of demographic factors like socioeconomic status and access to healthcare, race itself may predict disparate outcomes between patients.
In April 2022, FDA issued proposed product standards banning menthol flavoring in cigarettes and cigars; however, the benefits of these product standards could be weakened by the role of substitute products still available in the market.
In a study published in Science, UCSF researchers Kevin Lou, Luke Gilbert, and Kevan Shokat demonstrated the discovery of a cellular uptake pathway important for large and complex molecules, which bind in unconventional ways to their targets and are efficiently taken up by target cells.
Cancer Research UK, The University of Manchester, and Roche Products Ltd. opened a multi-drug, precision medicine trial for people with rare cancers who need more treatment options. The trial is set up to recruit both pediatric and adult patients with any rare cancer type.
Martha Donoghue was named associate director of pediatric oncology and rare cancers in the FDA Oncology Center of Excellence.
William K. Oh, a genitourinary oncologist with expertise in the use of systemic treatments for prostate cancer, was named chief medical officer of the Prostate Cancer Foundation.
UPMC Hillman Cancer Center named Charles Edward Geyer, Jr., Monica L. Baskin, and Kathryn H. Schmitz to leadership positions.
Ulrich Steidl, an expert in cancer and stem cell biology, has been named the chair of the department of cell biology at Albert Einstein College of Medicine. Steidl assumes his new position as Arthur Skoultchi, who has led the department for 24 years, steps down from departmental leadership.
